Already a member? Sign in
Riluzole is the first drug to be approved for amyotrophic lateral sclerosis (ALS). Riluzole, available as RilutekĀ®, does not cure ALS or improve symptoms, but may extend survival or the time to tracheostomy.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| ALS (Amyotrophic Lateral Sclerosis) | 1382 | 264 |
|
|
|
|
|
| PMA (Progressive Muscular Atrophy) | 29 | 13 |
|
|
|
||
| PLS (Primary Lateral Sclerosis) | 23 | 5 |
|
||||
| Other | 15 | 1 |
|
||||
| General health | 13 | 4 |
|
|
|
||
| Don't know | 8 | 1 |
|
See all 1136 patients currently taking Riluzole
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Riluzole
| Fatigue | 27 | |
|---|---|---|
| Nausea | 16 | |
| Stomach pain | 9 | |
| Abdominal pain | 8 | |
| Tiredness | 7 | |
| Weakness in lips | 7 | |
| See all 67 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Riluzole. See all 25 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 137 | ||
| Did not seem to work | 130 | ||
| Expense | 61 | ||
| Other | 49 | ||
| Doctor's advice | 46 | ||
| Personal research | 35 | ||
| Not indicated | 12 | ||
| Course of treatment ended | 9 | ||
| Change in health plan coverage | 6 |
Adherence
Taking treatment as prescribed
Adherence of Riluzole
Always |
248 | 84% |
|
|---|---|---|---|
Usually |
24 | 8% |
|
Sometimes |
9 | 3% |
|
Never |
15 | 5% |
|
Burden
Difficulty being on treatment
Burden of Riluzole
Very |
6 | 2% |
|
|---|---|---|---|
Somewhat |
31 | 10% |
|
A little |
54 | 18% |
|
Not at all |
205 | 69% |
|
Cost
Paid out of pocket
Cost of Riluzole
$200+ |
50 | 24% |
|
|---|---|---|---|
$100-199 |
10 | 5% |
|
$50-99 |
23 | 11% |
|
$25-49 |
31 | 15% |
|
< $25 |
94 | 45% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 09, 2012.